psilocybin has been researched along with escitalopram in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 8 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Becker, AM; Duthaler, U; Eckert, A; Grandinetti, T; Grünblatt, E; Holze, F; Klaiber, A; Kolaczynska, KE; Liechti, ME; Toedtli, VE; Varghese, N | 1 |
| O'Leary, K | 1 |
| Strous, JFM | 1 |
| Carhart-Harris, R; Daws, RE; Erritzoe, D; Giribaldi, B; Nutt, D; Roseman, L; Sexton, JD; Timmermann, C; Wall, MB | 1 |
| Carhart-Harris, RL; Erritzoe, D; Giribaldi, B; Nutt, DJ; Weiss, B | 1 |
| Botvinnik, A; Lerer, B; Lifschytz, T; Lotan, A; Saban, M; Salama, A; Shahar, O; Singh, S; Wolf, G; Yakobi, C | 1 |
| Carhart-Harris, R; Carlbring, P; Davis, AK; Erritzoe, D; Goldberg, SB; Griffiths, RR; Nutt, DJ; Simonsson, O | 1 |
| Ibrahim, IB; Straszek, SPV; Videbech, P | 1 |
2 review(s) available for psilocybin and escitalopram
| Article | Year |
|---|---|
Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: A systematic review and individual participant data meta-analysis.
Topics: Depression; Escitalopram; Hallucinogens; Humans; Psilocybin; Sample Size; Symptom Flare Up | 2023 |
Topics: Escitalopram; Hallucinogens; Humans; Ketamine; Mental Disorders; Psilocybin | 2023 |
3 trial(s) available for psilocybin and escitalopram
| Article | Year |
|---|---|
Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects.
Topics: Antidepressive Agents; Brain-Derived Neurotrophic Factor; Citalopram; Cross-Over Studies; Double-Blind Method; Escitalopram; Healthy Volunteers; Humans; Psilocybin | 2022 |
[Psilocybin compared with escitalopram for depression].
Topics: Depression; Escitalopram; Hallucinogens; Humans; Psilocybin; Psychiatry | 2022 |
Increased global integration in the brain after psilocybin therapy for depression.
Topics: Antidepressive Agents; Brain; Depression; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Hallucinogens; Humans; Psilocybin | 2022 |
3 other study(ies) available for psilocybin and escitalopram
| Article | Year |
|---|---|
Psychiatry goes psychedelic.
Topics: Clinical Trials, Phase II as Topic; Depression; Escitalopram; Hallucinogens; Humans; Psilocybin; Psychiatry; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors | 2021 |
A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression.
Topics: Clinical Trials as Topic; Depression; Depressive Disorder, Major; Escitalopram; Humans; Psilocybin; Psychiatric Status Rating Scales; Reproducibility of Results | 2023 |
Effect of psilocybin on marble burying in ICR mice: role of 5-HT1A receptors and implications for the treatment of obsessive-compulsive disorder.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Buspirone; Escitalopram; Hallucinogens; Male; Mice; Mice, Inbred ICR; Obsessive-Compulsive Disorder; Psilocybin; Receptor, Serotonin, 5-HT1A; Serotonin | 2023 |